

b) a closed circular plasmid vector comprising a desired gene; and

c) an ingredient selected from the group consisting of arginine, lysine, asparatic acid, glutamine, glutamic acid, histidine, proline, maltitol, lactose, glucose, sorbitol, xylitol, and a salt thereof.

31. (new) The stable gene formulation of claim 30 wherein the ingredient is selected from the group of arginine, asparatic acid, glutamine, glutamic acid, histidine, glucose, sorbitol, xylitol, and a salt thereof.

32. (new) The stable gene formulation of claim 30, further comprising a cationic lipid, a cationic polymer, or a hydrophobic polymer.

33. (new) The stable gene formulation of claim 30, wherein the formulation is in a rod form.

34. (new) A stable gene formulation lyophilized from an aqueous solution comprising:

- a) a closed circular plasmid vector comprising a desired gene; and
- b) citric acid, tartaric acid or a mixture thereof.

35. (new) The stable gene formulation of claim 34, further comprising an atelocollagen.

36. (new) The stable gene formulation of claim 34 or 35, further comprising a cationic lipid, a cationic polymer, or a hydrophobic polymer.--